Global Drugs for Herpes Labialis (Oral Herpes) Market Research Report 2024 - Future Opportunities, Latest Trends, In-depth Analysis, and Forecast To 2031
ReportID: 543281
|
Published Date: 2024/07/06
|
No. of Pages: 165
|
Categories: Life Sciences
|
Format : 
The global Drugs for Herpes Labialis (Oral Herpes) market was valued at 198.29 Million USD in 2020 and will grow with a CAGR of 5.26% from 2020 to 2027, based on HNY Research newly published report.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2-3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.Herpes Simplex Virus (HSV) is a commonly found human pathogen. Globally, an estimated 4.0 billion people are infected with Herpes Virus. The incidence rate of cold sores, caused by the HSV1 virus, is the second largest worldwide, trailing only behind common cold. About 79% of the US population is infected with HSV1, with about 25-35% of the adults enduring recurrent spate of cold sores. In all, close to 100 million outbreaks of cold sores occur each year in the US. The classification of drugs for herpes labialis (oral herpes) includes valacyclovir, aciclovir, famciclovir, docosanol and other. The proportion of aciclovir in 2016 is about 17%, and the proportion of valacyclovir is about 45%. Drugs for herpes labialis (oral herpes) are widely used though external use, oral and injection. The most proportion of drugs for herpes labialis (oral herpes) is oral, and the consumption in 2016 is about 1200 M USD. North America is the largest consumption place, with a revenue market share nearly 36.5% in 2016. Following North America, Europe is the second largest consumption place with the revenue market share of 28.4%. Market competition is intense. GSK, Novartis, Teva, Mylan, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
By Market Verdors:
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun Group
Hikma
Haiwang
Carmex
Cipher
By Types:
Aciclovir
Valacyclovir
Famciclovir
Docosanol
By Applications:
External Use
Oral
Injection
Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.
The prime objective of this report is to provide the insights on the post COVID-19 impact which will help market players in this field evaluate their business approaches. Also, this report covers market segmentation by major market verdors, types, applications/end users and geography(North America, East Asia, Europe, South Asia, Southeast Asia, Middle East, Africa, Oceania, South America).
Herpes Labialis (Oral Herpes) is a type of herpes simplex occurring on the lip, i.e. an infection caused by herpes simplex virus (HSV). An outbreak typically causes small blisters or sores on or around the mouth. The sores typically heal within 2-3 weeks, but the herpes virus remains dormant in the facial nerves, following orofacial infection, periodically reactivating (in symptomatic people) to create sores in the same area of the mouth or face at the site of the original infection.Herpes Simplex Virus (HSV) is a commonly found human pathogen. Globally, an estimated 4.0 billion people are infected with Herpes Virus. The incidence rate of cold sores, caused by the HSV1 virus, is the second largest worldwide, trailing only behind common cold. About 79% of the US population is infected with HSV1, with about 25-35% of the adults enduring recurrent spate of cold sores. In all, close to 100 million outbreaks of cold sores occur each year in the US. The classification of drugs for herpes labialis (oral herpes) includes valacyclovir, aciclovir, famciclovir, docosanol and other. The proportion of aciclovir in 2016 is about 17%, and the proportion of valacyclovir is about 45%. Drugs for herpes labialis (oral herpes) are widely used though external use, oral and injection. The most proportion of drugs for herpes labialis (oral herpes) is oral, and the consumption in 2016 is about 1200 M USD. North America is the largest consumption place, with a revenue market share nearly 36.5% in 2016. Following North America, Europe is the second largest consumption place with the revenue market share of 28.4%. Market competition is intense. GSK, Novartis, Teva, Mylan, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers; have been formed in the monopoly position in the industry.
By Market Verdors:
GSK
Novartis
Teva
Mylan
Cadila
Apotex
Daewoong Pharmaceutical
Livzon
Luoxin
Med shine
Bayer (Campho Phenique)
Blistex
Kelun Group
Hikma
Haiwang
Carmex
Cipher
By Types:
Aciclovir
Valacyclovir
Famciclovir
Docosanol
By Applications:
External Use
Oral
Injection
Key Indicators Analysed
Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market’s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Key Reasons to Purchase
To gain insightful analyses of the market and have comprehensive understanding of the global market and its commercial landscape.
Assess the production processes, major issues, and solutions to mitigate the development risk.
To understand the most affecting driving and restraining forces in the market and its impact in the global market.
Learn about the market strategies that are being adopted by leading respective organizations.
To understand the future outlook and prospects for the market.
Besides the standard structure reports, we also provide custom research according to specific requirements.
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Drugs for Herpes Labialis (Oral Herpes) Revenue
1.4 Market Analysis by Type
1.4.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 Aciclovir
1.4.3 Valacyclovir
1.4.4 Famciclovir
1.4.5 Docosanol
1.5 Market by Application
1.5.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Application: 2022-2027
1.5.2 External Use
1.5.3 Oral
1.5.4 Injection
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Drugs for Herpes Labialis (Oral Herpes) Market
1.8.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Drugs for Herpes Labialis (Oral Herpes) Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Drugs for Herpes Labialis (Oral Herpes) Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Drugs for Herpes Labialis (Oral Herpes) Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales Volume Market Share by Region (2016-2021)
3.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales Revenue Market Share by Region (2016-2021)
3.3 North America Drugs for Herpes Labialis (Oral Herpes) Sales Volume
3.3.1 North America Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.3.2 North America Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume
3.4.1 East Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Drugs for Herpes Labialis (Oral Herpes) Sales Volume (2016-2021)
3.5.1 Europe Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume (2016-2021)
3.6.1 South Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume (2016-2021)
3.7.1 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Drugs for Herpes Labialis (Oral Herpes) Sales Volume (2016-2021)
3.8.1 Middle East Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Drugs for Herpes Labialis (Oral Herpes) Sales Volume (2016-2021)
3.9.1 Africa Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Drugs for Herpes Labialis (Oral Herpes) Sales Volume (2016-2021)
3.10.1 Oceania Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Drugs for Herpes Labialis (Oral Herpes) Sales Volume (2016-2021)
3.11.1 South America Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.11.2 South America Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Drugs for Herpes Labialis (Oral Herpes) Sales Volume (2016-2021)
3.12.1 Rest of the World Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales Volume Market Share by Type (2016-2021)
14.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales Revenue Market Share by Type (2016-2021)
14.3 Global Drugs for Herpes Labialis (Oral Herpes) Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Drugs for Herpes Labialis (Oral Herpes) Consumption Volume by Application (2016-2021)
15.2 Global Drugs for Herpes Labialis (Oral Herpes) Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Drugs for Herpes Labialis (Oral Herpes) Business
16.1 GSK
16.1.1 GSK Company Profile
16.1.2 GSK Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.1.3 GSK Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Novartis
16.2.1 Novartis Company Profile
16.2.2 Novartis Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.2.3 Novartis Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 Teva
16.3.1 Teva Company Profile
16.3.2 Teva Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.3.3 Teva Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Mylan
16.4.1 Mylan Company Profile
16.4.2 Mylan Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.4.3 Mylan Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Cadila
16.5.1 Cadila Company Profile
16.5.2 Cadila Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.5.3 Cadila Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Apotex
16.6.1 Apotex Company Profile
16.6.2 Apotex Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.6.3 Apotex Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 Daewoong Pharmaceutical
16.7.1 Daewoong Pharmaceutical Company Profile
16.7.2 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.7.3 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 Livzon
16.8.1 Livzon Company Profile
16.8.2 Livzon Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.8.3 Livzon Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.9 Luoxin
16.9.1 Luoxin Company Profile
16.9.2 Luoxin Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.9.3 Luoxin Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.10 Med shine
16.10.1 Med shine Company Profile
16.10.2 Med shine Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.10.3 Med shine Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.11 Bayer (Campho Phenique)
16.11.1 Bayer (Campho Phenique) Company Profile
16.11.2 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.11.3 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.12 Blistex
16.12.1 Blistex Company Profile
16.12.2 Blistex Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.12.3 Blistex Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.13 Kelun Group
16.13.1 Kelun Group Company Profile
16.13.2 Kelun Group Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.13.3 Kelun Group Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.14 Hikma
16.14.1 Hikma Company Profile
16.14.2 Hikma Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.14.3 Hikma Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.15 Haiwang
16.15.1 Haiwang Company Profile
16.15.2 Haiwang Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.15.3 Haiwang Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.16 Carmex
16.16.1 Carmex Company Profile
16.16.2 Carmex Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.16.3 Carmex Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.17 Cipher
16.17.1 Cipher Company Profile
16.17.2 Cipher Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.17.3 Cipher Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Drugs for Herpes Labialis (Oral Herpes) Manufacturing Cost Analysis
17.1 Drugs for Herpes Labialis (Oral Herpes) Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Drugs for Herpes Labialis (Oral Herpes)
17.4 Drugs for Herpes Labialis (Oral Herpes) Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Drugs for Herpes Labialis (Oral Herpes) Distributors List
18.3 Drugs for Herpes Labialis (Oral Herpes) Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Drugs for Herpes Labialis (Oral Herpes) (2022-2027)
20.2 Global Forecasted Revenue of Drugs for Herpes Labialis (Oral Herpes) (2022-2027)
20.3 Global Forecasted Price of Drugs for Herpes Labialis (Oral Herpes) (2016-2027)
20.4 Global Forecasted Production of Drugs for Herpes Labialis (Oral Herpes) by Region (2022-2027)
20.4.1 North America Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.3 Europe Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.7 Africa Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.9 South America Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
21.2 East Asia Market Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
21.3 Europe Market Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Countriy
21.4 South Asia Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
21.5 Southeast Asia Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
21.6 Middle East Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
21.7 Africa Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
21.8 Oceania Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
21.9 South America Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
21.10 Rest of the world Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Drugs for Herpes Labialis (Oral Herpes) Revenue
1.4 Market Analysis by Type
1.4.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Size Growth Rate by Type: 2021 VS 2027
1.4.2 Aciclovir
1.4.3 Valacyclovir
1.4.4 Famciclovir
1.4.5 Docosanol
1.5 Market by Application
1.5.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Share by Application: 2022-2027
1.5.2 External Use
1.5.3 Oral
1.5.4 Injection
1.6 Study Objectives
1.7 Years Considered
1.8 Overview of Global Drugs for Herpes Labialis (Oral Herpes) Market
1.8.1 Global Drugs for Herpes Labialis (Oral Herpes) Market Status and Outlook (2016-2027)
1.8.2 North America
1.8.3 East Asia
1.8.4 Europe
1.8.5 South Asia
1.8.6 Southeast Asia
1.8.7 Middle East
1.8.8 Africa
1.8.9 Oceania
1.8.10 South America
1.8.11 Rest of the World
2 Market Competition by Manufacturers
2.1 Global Drugs for Herpes Labialis (Oral Herpes) Production Capacity Market Share by Manufacturers (2016-2021)
2.2 Global Drugs for Herpes Labialis (Oral Herpes) Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Drugs for Herpes Labialis (Oral Herpes) Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Drugs for Herpes Labialis (Oral Herpes) Production Sites, Area Served, Product Type
3 Sales by Region
3.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales Volume Market Share by Region (2016-2021)
3.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales Revenue Market Share by Region (2016-2021)
3.3 North America Drugs for Herpes Labialis (Oral Herpes) Sales Volume
3.3.1 North America Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.3.2 North America Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.4 East Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume
3.4.1 East Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.4.2 East Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.5 Europe Drugs for Herpes Labialis (Oral Herpes) Sales Volume (2016-2021)
3.5.1 Europe Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.5.2 Europe Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.6 South Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume (2016-2021)
3.6.1 South Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.6.2 South Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.7 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume (2016-2021)
3.7.1 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.7.2 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.8 Middle East Drugs for Herpes Labialis (Oral Herpes) Sales Volume (2016-2021)
3.8.1 Middle East Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.8.2 Middle East Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.9 Africa Drugs for Herpes Labialis (Oral Herpes) Sales Volume (2016-2021)
3.9.1 Africa Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.9.2 Africa Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.10 Oceania Drugs for Herpes Labialis (Oral Herpes) Sales Volume (2016-2021)
3.10.1 Oceania Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.10.2 Oceania Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.11 South America Drugs for Herpes Labialis (Oral Herpes) Sales Volume (2016-2021)
3.11.1 South America Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.11.2 South America Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
3.12 Rest of the World Drugs for Herpes Labialis (Oral Herpes) Sales Volume (2016-2021)
3.12.1 Rest of the World Drugs for Herpes Labialis (Oral Herpes) Sales Volume Growth Rate (2016-2021)
3.12.2 Rest of the World Drugs for Herpes Labialis (Oral Herpes) Sales Volume Capacity, Revenue, Price and Gross Margin (2016-2021)
4 North America
4.1 North America Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
4.2 United States
4.3 Canada
4.4 Mexico
5 East Asia
5.1 East Asia Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
5.2 China
5.3 Japan
5.4 South Korea
6 Europe
6.1 Europe Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
6.2 Germany
6.3 United Kingdom
6.4 France
6.5 Italy
6.6 Russia
6.7 Spain
6.8 Netherlands
6.9 Switzerland
6.10 Poland
7 South Asia
7.1 South Asia Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
7.2 India
7.3 Pakistan
7.4 Bangladesh
8 Southeast Asia
8.1 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
8.2 Indonesia
8.3 Thailand
8.4 Singapore
8.5 Malaysia
8.6 Philippines
8.7 Vietnam
8.8 Myanmar
9 Middle East
9.1 Middle East Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
9.2 Turkey
9.3 Saudi Arabia
9.4 Iran
9.5 United Arab Emirates
9.6 Israel
9.7 Iraq
9.8 Qatar
9.9 Kuwait
9.10 Oman
10 Africa
10.1 Africa Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
10.2 Nigeria
10.3 South Africa
10.4 Egypt
10.5 Algeria
10.6 Morocco
11 Oceania
11.1 Oceania Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
11.2 Australia
11.3 New Zealand
12 South America
12.1 South America Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
12.2 Brazil
12.3 Argentina
12.4 Columbia
12.5 Chile
12.6 Venezuela
12.7 Peru
12.8 Puerto Rico
12.9 Ecuador
13 Rest of the World
13.1 Rest of the World Drugs for Herpes Labialis (Oral Herpes) Consumption by Countries
13.2 Kazakhstan
14 Sales Volume, Sales Revenue, Sales Price Trend by Type
14.1 Global Drugs for Herpes Labialis (Oral Herpes) Sales Volume Market Share by Type (2016-2021)
14.2 Global Drugs for Herpes Labialis (Oral Herpes) Sales Revenue Market Share by Type (2016-2021)
14.3 Global Drugs for Herpes Labialis (Oral Herpes) Sales Price by Type (2016-2021)
15 Consumption Analysis by Application
15.1 Global Drugs for Herpes Labialis (Oral Herpes) Consumption Volume by Application (2016-2021)
15.2 Global Drugs for Herpes Labialis (Oral Herpes) Consumption Value by Application (2016-2021)
16 Company Profiles and Key Figures in Drugs for Herpes Labialis (Oral Herpes) Business
16.1 GSK
16.1.1 GSK Company Profile
16.1.2 GSK Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.1.3 GSK Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.2 Novartis
16.2.1 Novartis Company Profile
16.2.2 Novartis Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.2.3 Novartis Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.3 Teva
16.3.1 Teva Company Profile
16.3.2 Teva Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.3.3 Teva Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.4 Mylan
16.4.1 Mylan Company Profile
16.4.2 Mylan Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.4.3 Mylan Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.5 Cadila
16.5.1 Cadila Company Profile
16.5.2 Cadila Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.5.3 Cadila Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.6 Apotex
16.6.1 Apotex Company Profile
16.6.2 Apotex Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.6.3 Apotex Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.7 Daewoong Pharmaceutical
16.7.1 Daewoong Pharmaceutical Company Profile
16.7.2 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.7.3 Daewoong Pharmaceutical Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.8 Livzon
16.8.1 Livzon Company Profile
16.8.2 Livzon Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.8.3 Livzon Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.9 Luoxin
16.9.1 Luoxin Company Profile
16.9.2 Luoxin Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.9.3 Luoxin Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.10 Med shine
16.10.1 Med shine Company Profile
16.10.2 Med shine Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.10.3 Med shine Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.11 Bayer (Campho Phenique)
16.11.1 Bayer (Campho Phenique) Company Profile
16.11.2 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.11.3 Bayer (Campho Phenique) Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.12 Blistex
16.12.1 Blistex Company Profile
16.12.2 Blistex Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.12.3 Blistex Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.13 Kelun Group
16.13.1 Kelun Group Company Profile
16.13.2 Kelun Group Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.13.3 Kelun Group Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.14 Hikma
16.14.1 Hikma Company Profile
16.14.2 Hikma Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.14.3 Hikma Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.15 Haiwang
16.15.1 Haiwang Company Profile
16.15.2 Haiwang Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.15.3 Haiwang Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.16 Carmex
16.16.1 Carmex Company Profile
16.16.2 Carmex Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.16.3 Carmex Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
16.17 Cipher
16.17.1 Cipher Company Profile
16.17.2 Cipher Drugs for Herpes Labialis (Oral Herpes) Product Specification
16.17.3 Cipher Drugs for Herpes Labialis (Oral Herpes) Production Capacity, Revenue, Price and Gross Margin (2016-2021)
17 Drugs for Herpes Labialis (Oral Herpes) Manufacturing Cost Analysis
17.1 Drugs for Herpes Labialis (Oral Herpes) Key Raw Materials Analysis
17.1.1 Key Raw Materials
17.2 Proportion of Manufacturing Cost Structure
17.3 Manufacturing Process Analysis of Drugs for Herpes Labialis (Oral Herpes)
17.4 Drugs for Herpes Labialis (Oral Herpes) Industrial Chain Analysis
18 Marketing Channel, Distributors and Customers
18.1 Marketing Channel
18.2 Drugs for Herpes Labialis (Oral Herpes) Distributors List
18.3 Drugs for Herpes Labialis (Oral Herpes) Customers
19 Market Dynamics
19.1 Market Trends
19.2 Opportunities and Drivers
19.3 Challenges
19.4 Porter's Five Forces Analysis
20 Production and Supply Forecast
20.1 Global Forecasted Production of Drugs for Herpes Labialis (Oral Herpes) (2022-2027)
20.2 Global Forecasted Revenue of Drugs for Herpes Labialis (Oral Herpes) (2022-2027)
20.3 Global Forecasted Price of Drugs for Herpes Labialis (Oral Herpes) (2016-2027)
20.4 Global Forecasted Production of Drugs for Herpes Labialis (Oral Herpes) by Region (2022-2027)
20.4.1 North America Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.2 East Asia Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.3 Europe Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.4 South Asia Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.5 Southeast Asia Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.6 Middle East Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.7 Africa Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.8 Oceania Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.9 South America Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.4.10 Rest of the World Drugs for Herpes Labialis (Oral Herpes) Production, Revenue Forecast (2022-2027)
20.5 Forecast by Type and by Application (2022-2027)
20.5.1 Global Sales Volume, Sales Revenue and Sales Price Forecast by Type (2022-2027)
20.5.2 Global Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Application (2022-2027)
21 Consumption and Demand Forecast
21.1 North America Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
21.2 East Asia Market Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
21.3 Europe Market Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Countriy
21.4 South Asia Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
21.5 Southeast Asia Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
21.6 Middle East Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
21.7 Africa Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
21.8 Oceania Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
21.9 South America Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
21.10 Rest of the world Forecasted Consumption of Drugs for Herpes Labialis (Oral Herpes) by Country
22 Research Findings and Conclusion
23 Methodology and Data Source
23.1 Methodology/Research Approach
23.1.1 Research Programs/Design
23.1.2 Market Size Estimation
23.1.3 Market Breakdown and Data Triangulation
23.2 Data Source
23.2.1 Secondary Sources
23.2.2 Primary Sources
23.3 Disclaimer
Published On:2024/07/06
Base Year:
Historical Data:
No of Pages:165
Price
Global Drugs for Herpes Labialis (Oral Herpes) Market Research Report 2024 - Future Opportunities, Latest Trends, In-depth Analysis, and Forecast To 2031
A2Z Market Research is one of the leading providers of market intelligence products and services. We offer reports on over 10+ industries and update our collection daily which helps our clients to access database of expert market insights on global industries, companies, products, and trends.
Subscribe Us
Sign up today for tips and latest news
and exclusive special offers.
